Research

Hormonal

Gastrointestinal adverse events (nausea, vomiting, diarrhea, dyspepsia) associated with tirzepatide contribute minimally (up to 3.1%) to total weight reduction, with weight loss occurring similarly in patients with and without these symptoms.

Do not expect nausea or vomiting to drive your weight loss. Clinical data shows that patients who experience no gastrointestinal side effects lose just as much weight as those who do. Focus on the hormonal mechanism of the drug rather than tolerating discomfort as a sign of efficacy.

GoodQualifiesHIGH confidence
Mediation analyses suggested that N/V/D and dyspepsia were associated with up to 3.1% of total weight reduction... Weight reduction with tirzepatide was similar among participants reporting no nausea, nausea alone, or any N/V/D.
Domenica Rubino et al. · Diabetes Obesity and Metabolism · 2025

Why this rating

Based on pooled Phase 3 trials (SURMOUNT-1 to -4) with large sample sizes, though the analysis is post hoc and not controlled for multiplicity.

Source

Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the <scp>SURMOUNT</scp> ‐1 to ‐4 trials

Domenica Rubino et al. · Diabetes Obesity and Metabolism · 2025

DOI 10.1111/dom.16176

rct · n=4726Cited 14×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →